NasdaqGS:MRTX

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. More Details


Snowflake Analysis

Flawless balance sheet and slightly overvalued.

Share Price & News

How has Mirati Therapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: MRTX's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-7.5%

MRTX

-1.2%

US Biotechs

0.4%

US Market


1 Year Return

121.2%

MRTX

32.5%

US Biotechs

17.8%

US Market

Return vs Industry: MRTX exceeded the US Biotechs industry which returned 32.5% over the past year.

Return vs Market: MRTX exceeded the US Market which returned 17.8% over the past year.


Shareholder returns

MRTXIndustryMarket
7 Day-7.5%-1.2%0.4%
30 Day7.7%2.3%6.1%
90 Day51.2%-2.6%8.9%
1 Year121.2%121.2%34.7%32.5%20.5%17.8%
3 Year1,270.3%1,270.3%20.0%14.0%42.3%32.9%
5 Year371.6%371.6%11.5%3.4%84.2%63.4%

Price Volatility Vs. Market

How volatile is Mirati Therapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Mirati Therapeutics undervalued compared to its fair value and its price relative to the market?

31.7%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: MRTX ($180.2) is trading below our estimate of fair value ($263.74)

Significantly Below Fair Value: MRTX is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: MRTX is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: MRTX is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate MRTX's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: MRTX is overvalued based on its PB Ratio (13.2x) compared to the US Biotechs industry average (3.4x).


Next Steps

Future Growth

How is Mirati Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 12 analysts?

50.0%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: MRTX is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: MRTX is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: MRTX is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: MRTX's revenue (84.9% per year) is forecast to grow faster than the US market (9.9% per year).

High Growth Revenue: MRTX's revenue (84.9% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if MRTX's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Mirati Therapeutics performed over the past 5 years?

-32.2%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: MRTX is currently unprofitable.

Growing Profit Margin: MRTX is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: MRTX is unprofitable, and losses have increased over the past 5 years at a rate of 32.2% per year.

Accelerating Growth: Unable to compare MRTX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: MRTX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-7.1%).


Return on Equity

High ROE: MRTX has a negative Return on Equity (-48.95%), as it is currently unprofitable.


Next Steps

Financial Health

How is Mirati Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: MRTX's short term assets ($654.0M) exceed its short term liabilities ($57.7M).

Long Term Liabilities: MRTX's short term assets ($654.0M) exceed its long term liabilities ($1.3M).


Debt to Equity History and Analysis

Debt Level: MRTX is debt free.

Reducing Debt: MRTX has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: MRTX has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: MRTX has sufficient cash runway for 3 years if free cash flow continues to reduce at historical rates of 26.9% each year.


Next Steps

Dividend

What is Mirati Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate MRTX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate MRTX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if MRTX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if MRTX's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of MRTX's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

0.8yrs

Average management tenure


CEO

Charles Baum (62 yo)

7.92yrs

Tenure

US$8,484,393

Compensation

Dr. Charles M. Baum, M.D., Ph.D. has been a Director at Immunomedics, Inc. since February 23, 2019. Dr. Baum currently serves as Director of BCTG Acquisition Corp. He has been the Chief Executive Officer a ...


CEO Compensation Analysis

Compensation vs Market: Charles's total compensation ($USD8.48M) is about average for companies of similar size in the US market ($USD7.31M).

Compensation vs Earnings: Charles's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Charles Baum
President7.92yrsUS$8.48m0.14%
$ 11.2m
James Christensen
Chief Scientific Officer & Executive VP6.75yrsUS$3.29m0.039%
$ 3.1m
Daniel Faga
Executive VP0.75yrno datano data
Vickie Reed
Senior VP of Technical Operation & Chief Accounting Officer0.75yrno datano data
Temre Johnson
Director of Investor Relations & Corporate Communicationsno datano datano data
Reena Desai
VP, General Counsel & Corporate Secretary0.75yrno datano data
Matthew Marx
VP & Head of Drug Discovery2.75yrsno datano data
Philip Roberts
Senior Vice President of Technical Operations1.42yrsno datano data
Benjamin Hickey
Executive VP & Chief Commercial Officer0.75yrno datano data
Kelly Covello
VP & Head of Medical Affairs0.50yrno datano data
Ryan Asay
VP & Head of Corporate Affairs0.50yrno datano data
Allen Albright
Head of Regulatory Affairs and VP of Regulatory Affairs & Quality Assurance6.75yrsno datano data

0.8yrs

Average Tenure

52yo

Average Age

Experienced Management: MRTX's management team is not considered experienced ( 0.8 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Charles Baum
President7.92yrsUS$8.48m0.14%
$ 11.2m
Michael Grey
Independent Director5.92yrsUS$589.67k0.0051%
$ 406.9k
Henry Fuchs
Independent Director8.67yrsUS$603.17k0.0045%
$ 360.4k
Bruce L. Carter
Independent Director4.08yrsUS$606.67k0.0045%
$ 360.4k
George Demetri
Member of Scientific Advisory Boardno datano datano data
Faheem Hasnain
Chairman of the Board1.67yrsUS$2.65m0%
$ 0
Stephen Baylin
Member of Scientific Advisory Boardno datano datano data
Lillian Siu
Member of Scientific Advisory Boardno datano datano data
Aaron Davis
Independent Director1.83yrsUS$579.67k0.088%
$ 7.0m
Craig Johnson
Independent Director7.08yrsUS$605.17k0.0045%
$ 360.4k
Channing Der
Member of Scientific Advisory Board1.75yrsno datano data
Maria Martinez-Davis
Independent Director1.83yrsUS$592.67k0%
$ 0

4.1yrs

Average Tenure

62yo

Average Age

Experienced Board: MRTX's board of directors are considered experienced (4.1 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 13.3%.


Top Shareholders

Company Information

Mirati Therapeutics, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Mirati Therapeutics, Inc.
  • Ticker: MRTX
  • Exchange: NasdaqGS
  • Founded: 1995
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$8.026b
  • Shares outstanding: 44.54m
  • Website: https://www.mirati.com

Number of Employees


Location

  • Mirati Therapeutics, Inc.
  • 9393 Towne Centre Drive
  • Suite 200
  • San Diego
  • California
  • 92121
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
MRTXNasdaqGS (Nasdaq Global Select)YesCommon SharesUSUSDJun 2004
26MDB (Deutsche Boerse AG)YesCommon SharesDEEURJun 2004

Biography

Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. It is developing MRTX849, a KRAS ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/10/26 05:12
End of Day Share Price2020/10/23 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.